Poxel SA Market Cap ($9.79 Million)
Market Cap & Net Worth: Poxel SA (POXEL)
Poxel SA market cap. Poxel SA (PA:POXEL) has a market capitalization of $9.79 Million (€8.37 Million) as of November 7, 2026. Listed on the PA stock exchange, this France-based company holds position #26970 globally and #461 in its home market, demonstrating a -3.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Poxel SA's stock price €0.16 by its total outstanding shares 53663304 (53.66 Million). Also see Poxel SA cash conversion from operations for how efficiently the company converts equity into cash flow.
Poxel SA Market Cap History (2015–2026)
Poxel SA market cap history from 2015 to 2026. Data shows change from $830.65 Million to $9.79 Million (-30.77% CAGR). Check latest Poxel SA stock price today for real-time trading data and today's change.
Index Memberships
Poxel SA is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$222.35 Billion | 0.00% | #106 of 119 |
|
CAC Small90
CACS
|
$35.74 Billion | 0.03% | #55 of 64 |
|
CAC All-Tradable
CACT
|
$2.82 Trillion | 0.00% | #166 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$2.82 Trillion | 0.00% | #166 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$2.82 Trillion | 0.00% | #166 of 179 |
|
CAC Health Care
FRHC
|
$266.99 Billion | 0.00% | #31 of 36 |
Weight: Poxel SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Poxel SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Poxel SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore POXEL net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.31x
Poxel SA's market cap is 1.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $830.65 Million | $59.65K | -$12.24 Million | 13925.43x | N/A |
| 2016 | $437.28 Million | $70.27K | -$24.48 Million | 6223.36x | N/A |
| 2017 | $412.19 Million | $5.29 Million | -$22.69 Million | 77.92x | N/A |
| 2018 | $319.34 Million | $74.61 Million | $13.53 Million | 4.28x | 23.61x |
| 2019 | $765.40 Million | $26.56 Million | -$25.74 Million | 28.82x | N/A |
| 2020 | $399.01 Million | $6.81 Million | -$31.86 Million | 58.63x | N/A |
| 2021 | $308.42 Million | $13.40 Million | -$23.76 Million | 23.02x | N/A |
| 2022 | $58.97 Million | $674.00K | -$31.40 Million | 87.50x | N/A |
| 2023 | $34.57 Million | $1.98 Million | -$35.09 Million | 17.45x | N/A |
| 2024 | $8.70 Million | $6.64 Million | -$18.30 Million | 1.31x | N/A |
Competitor Companies of POXEL by Market Capitalization
Companies near Poxel SA in the global market cap rankings as of November 7, 2026. Also see POXEL total asset value for a full breakdown of the balance sheet.
Key companies related to Poxel SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #176 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #364 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #405 globally with a market cap of $69.48 Billion USD ( AU$98.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #499 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #176 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $542.50 |
| #364 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $902.90 |
| #405 | CSL Ltd | AU:CSL | $69.48 Billion | AU$202.40 |
| #499 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $241.46 |
Market Capitalization of Poxel SA (2015–2026)
Market capitalization of Poxel SA from 2015 to today. Between 2015 and today, Poxel SA's market cap moved from $830.65 Million to $ 9.79 Million, with a yearly change of -30.77%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €9.79 Million | -33.33% |
| 2025 | €14.68 Million | +68.83% |
| 2024 | €8.70 Million | -74.85% |
| 2023 | €34.57 Million | -41.38% |
| 2022 | €58.97 Million | -80.88% |
| 2021 | €308.42 Million | -22.70% |
| 2020 | €399.01 Million | -47.87% |
| 2019 | €765.40 Million | +139.69% |
| 2018 | €319.34 Million | -22.53% |
| 2017 | €412.19 Million | -5.74% |
| 2016 | €437.28 Million | -47.36% |
| 2015 | €830.65 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 6th, 2026 the market cap of Poxel SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $9.79 Million USD |
| MoneyControl | $9.79 Million USD |
| MarketWatch | $9.79 Million USD |
| marketcap.company | $9.79 Million USD |
| Reuters | $9.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the tr… Read more